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Abstract
Hepatitis C virus (HCV) directly induces oxidative stress and liver injury. Bach1, a zipper (bZip)
mammalian transcriptional repressor, negatively regulates heme oxygenase 1 (HMOX1), a key
cytoprotective enzyme that has anti-oxidant and anti-inflammatory activities. microRNAs are
small non-coding RNAs (~22 nt) that are important regulators of gene expression. Whether and
how microRNAs regulate Bach1 or HCV are largely unknown. The aims of this study were to
determine whether miR-196 regulates Bach1, HMOX1, and/or HCV gene expression. HCV
replicon cell lines (Con1 and 9-13) of the Con1 isolate and J6/JFH1-based HCV cell culture
system were used in this study. The effects of miR-196 mimic on Bach1, HMOX1 and HCV RNA
and protein levels were measured by qRT-PCR and Western blots, respectively. The Dual Glo™
Luciferase Assay System was used to determine reporter activities. miR-196 mimic significantly
down-regulated Bach1 and up-regulated HMOX1 gene expression, and inhibited HCV expression.
Dual luciferase reporter assays demonstrated that transfection of miR-196 mimic resulted in a
significant decrease in Bach1 3′-UTR-dependent luciferase activity but not in mutant Bach1 3′-
UTR-dependent luciferase activity. Moreover, there was no detectable effect of mutant miR-196
on Bach1 3′-UTR-dependent luciferase activity.
Conclusions—miR-196 directly acts on the 3′-UTR of Bach1 mRNA and translationally
represses the expression of this protein, and up-regulates HMOX1. miR-196 also inhibits HCV
expression in HCV replicon cell lines (genotype 1b) and in J6/JFH1 (genotype 2a) HCV cell
culture system. Thus, miR-196 plays a role in both HMOX1/Bach1 expression and the regulation
of HCV expression in human hepatocytes. Over-expression of miR-196 holds promise as a
potential novel strategy to prevent or ameliorate hepatitis C infection, and to protect against liver
injury in chronic HCV infection.
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Hepatitis C virus (HCV) infection is a world-wide health problem. The current standard
therapy for chronic hepatitis C (CHC) is a combination of pegylated interferon (IFN) and
ribavirin, but only ~50% of patients respond to such treatment, which is expensive,
prolonged, and attended by numerous unpleasant side-effects (1,2). There is a continuing
need to develop new anti-viral therapies. The molecular mechanisms underlying HCV-
associated liver injury remain imperfectly understood. However, studies have indicated that
HCV directly induces oxidative stress in hepatocytes through multiple mechanisms that
include chronic inflammation, increases in iron, and liver injury. Therefore oxidative stress
has emerged as an important pathogenetic mechanism in chronic hepatitis C (3–5), and
antioxidant and cytoprotective therapy has been proposed to treat hepatitis C.
Heme oxygenase 1 (HMOX1) is a key cytoprotective enzyme, catalyzing heme degradation
and generating ferrous iron, carbon monoxide and biliverdin, the latter two of which have
anti-oxidant and anti-inflammatory activities in vivo (6–8). Bach1, a basic leucine zipper
(bZip) mammalian transcriptional repressor of HMOX1, negatively regulates HMOX1 gene
expression. Bach1 forms antagonizing heterodimers with the Maf-related oncogene family.
These heterodimers bind to Maf recognition elements (MAREs) and suppress expression of
genes [e.g., HMOX1 and NAD(P)H:quinone oxidoreductase (NQO1)] (9–12).
microRNAs (miRNAs) are a class of small non-coding RNAs (~22 nt) that regulate gene
expression primarily through translational repression (13,14). The exact mechanism by
which target genes are down-regulated remains unclear. Sequence complementarity in the
6–8 base pair ‘seed regions’ at the end of miRNA-mRNA heteroduplexes seem to determine
the specificity of miRNA-target RNA interactions (15). miR-196 was first recognized to
have extensive and evolutionarily conserved complementarity to homeobox clusters, groups
of related transcription factor genes crucial for numerous developmental programs in
animals, and to regulate homeobox gene expression (16,17). A recent report indicated one
perfect match between miR-196 and non-structural (NS) 5A coding region of the HCV JFH1
genome (genotype 2a), and IFN β treatment resulted in significant induction of miR-196 in
the human hepatoma cell line Huh-7 and in primary murine hepatocytes (18). A search of
the TargetScan 4.2 data base revealed that at least two miR-196 seed match sites occur in the
3′-UTR of Bach1 mRNA. This led us to propose that miR-196 is a miRNA that targets the
HCV genome and the 3′-UTR of Bach1 mRNA, the latter leading to up-regulation of the
HMOX1 gene. These dual effects are analogous to effects of miR-122, recently reported
from our laboratory (19).
In the work reported here we experimentally validated the computational prediction of
miR-196 binding in the 3′-UTR of Bach 1 mRNA by luciferase reporter assay. miR-196
mimic significantly down-regulated Bach1 and up-regulated HMOX1 gene expression, and
inhibited HCV expression. These results suggest that up-regulation of miR-196 may be an
additional new therapeutic approach to prevent or ameliorate hepatitis C infection, and to
protect against liver injury in chronic HCV infection. The findings indicate that miR-196
plays a role in the regulation of HMOX1/Bach1 expression and HCV replication in
hepatocytes. They also add to the growing evidence that up-regulation of HMOX1 may be
beneficial in HCV infection (5,19,20).
MATERIALS AND METHODS
Cell Culture
9-13 cells were kindly provided by R. Bartenschlager (University of Heidelberg, Heidelberg,
Germany). 9-13 cells harbor a replicating HCV non-structural region with the use of the
NS3 -NS5B gene regions from the Con1 isolate (21). Huh-7.5 and Con1 subgenomic
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genotype 1b HCV replicon cell lines were from Apath LLC (St, Louis, MO). Huh-7.5 is a
highly permissive, alpha interferon-cured Huh-7 human hepatocellular carcinoma cell line
derivative. The Con1 cell line is a Huh-7.5 cell population containing the full-length HCV
genotype 1b replicon. The 9-13, Huh.7.5 and Con1 cells were maintained in DMEM
supplemented with 10% (v/v) FBS, 100 units/mL penicillin, 100 μg/mL streptomycin, and
selection antibiotic 500 μg/mL G418 for 9-13 cells, or 750 μg/mL G418 for Con1 cells.
microRNAs, siRNAs and Reporter Constructs
The miRIDIAN microRNA mimics for has-miR-196, has-miR-16, customized mutant has-
miR-196, miRNA mimic negative control (MMNC), and Bach1-siRNA were obtained from
Dharmacon (Lafayette, CO). pRL-TK vector was from Promega. The pRL-TK reporter
vector contains a cDNA (Rluc) encoding Renilla luciferase as an internal control reporter.
pGL3-Bach1 luciferase reporter construct, containing an 1837 bp fragment of Bach1 3′-
UTR, was a kind gift of Dr. Rolf Renne (University of Florida, Gainesville, FL) (22).
Mutant pGL3-Bach1 was generated by GENEWIZ, Inc. (South Plainfield, NJ). pLSV40-
Rluc and pLSV40-GL3/Bach1 reporter vectors were kindly provided by B. R. Cullen (Duke
University, Durham, NC). pLSV40-Rluc contains a cDNA (Rluc) encoding Renilla
luciferase as an internal control reporter and pLSV40-GL3/Bach1 firefly luciferase reporter
construct contains the full-length 3′-UTR of Bach1 mRNA (23). Constructs were confirmed
by restriction enzyme digestion and sequencing.
Transfection and Luciferase Activity Assays
Transfection of miR-196 mimic or Bach-siRNA was performed as described previously
(24). Co-transfection of microRNA mimics and reporters were carried out using
Lipofectamine 2000 from Invitrogen (Carlsbad, CA) according to manufacturer’s protocol.
Briefly, cells were co-transfected with 0.4 ug/mL of pGL3-Bach1 or mutant pGL3-Bach,
with 0.4 ug/mL of pRL-TK, and with 10–50 nM tested miRNAs. 24–48 h after transfection,
cells were harvested and lysed, and the luciferase reporter activities were measured using the
Dual-Glo® Luciferase Assay System. Firefly luciferase activity was normalized to Renilla
luciferase activity and total protein, determined using the BCA protein assay kit. For ease of
comparison, values for cells with pGL3-Bach1 and pRL-TK transfection were set equal to 1.
In Vitro Transcription, Transfection and Infection
The HCV infectious clone pJ6/JFH1, the full-length chimeric genome with the core-NS2
regions from the infectious J6 (genotype 2a) and NS3-NS5B regions from the infectious
JFH1 (genotype 2a), was generously provided by C. M. Rice (the Rockefeller University,
New York, NY). The production of J6/JFH1-based cell culture-generated HCV (HCVcc) has
been reported previously (25). In brief, the pJ6/JFH1 plasmid was linearized with XbaI, and
purified by ethanol precipitation, digestion with proteinase K, and phenol-chloroform
extraction. The linearized plasmid was used as a template for in vitro transcription using the
MEGAscript T7 kit (Ambion, Austin, TX). For HCV RNA transfection, Huh-7.5 cells were
plated in 24-well plates one day prior to transfection and transfected at 70~80% confluence.
Cells were transfected at an RNA/lipofectamine ratio of 1:2 by using 2 μg/well of HCV
RNA and 4 uL/well Lipofectamine 2000 for 48 h. To infect naïve Huh-7.5 cells, cell culture
supernatants from the cells transfected with HCV RNA for 48 h were collected and filtered
through a 0.20 μm filter, and added to cultures of naïve Huh-7.5 cells.
The pFK-Con1 construct (genotype 1b) (21) was a kind gift of Dr. R. Bartenschlager
(University of Heidelberg, Heidelberg, Germany). Mutant pFK-Con1 (pFK-Con1-Mut) with
mutations in four nucleotides in the putative binding sites for miR-196 was generated by
GENEWIZ, Inc. (South Plainfield, NJ) and confirmed by sequencing. pFK-Con1-WT and
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pFK-Con1-Mut were linearized with AseI and ScaI. In vitro transcription and transfection
were performed as described previously.
Western Blots
Western blots were performed using the standard protocols of our laboratory as reported
previously (10). The method is described in detail in Supplemental Materials and Methods
(see Supporting Information online).
Quantitative RT-PCR
Total RNA from tested cells was extracted and cDNA was synthesized (10). Real time
quantitative RT-PCR was carried out using primers as reported previously (19,26), and as
described in detail in Supplemental Material and Methods (see Supporting Information
online).
Statistical Analysis
Initial analysis showed that results were normally distributed. Therefore, parametric
statistical procedures were used. The Student’s t-test (for comparison of two conditions) or
analysis-of-variance (for comparisons among more than two) was used to analyze the
differences among means. Values of P <0.05 were considered statistically significant.
Experiments were repeated at least three times with similar results. All experiments included
at least triplicate samples for each treatment group. Representative results from single
experiments are presented. Statistical analyses were performed with JMP 4.0.4 software
from SAS Institute (Cary, NC).
RESULTS
Analysis in silico predicts two seed region matches of miR-196 and the 3′-UTR of Bach1
mRNA
An online search of the TargetScan 4.2 data base (http://www.targetscan.org/vert_42/)
demonstrated that at least two putative miR-196 seed match sites were harbored in the 3′-
UTR of Bach1 mRNA. As shown in Figure 1A & B, one of the predicted binding sites
(2280–2286 nt) was highly conserved in human, mouse, rat, chicken and dog, whereas the
other putative site (2161–2166 nt) was poorly conserved across species. No predicted
miR-196 binding sites were found in the Nrf2 and HMOX1 gene, and no putative miR-196
binding sites were found in the coding region of Bach1 gene (data not shown).
miR-196 down-regulates the transcriptional repressor Bach1 and up-regulates HMOX1 in
9-13 cells expressing HCV non-structural proteins
To experimentally verify that the putative miR-196 binding sites are functional, we
transfected 9-13 cells with miR-196 specific mimic and measured Bach1 protein and mRNA
levels by Western blots and qRT-PCR, respectively. 9-13 cells transfected with miR-196
mimic showed a significant reduction in the expression of Bach1 protein levels (~55% after
24 h transfection and ~64% after 48 h transfection), compared with miRNA mimic negative
control (MMNC), whereas no effects on Bach1 protein levels were detectable in cells
transfected with miRNA mimic negative control compared with mock transfection (Figure
2A). However, no significant effect of miR-196 on Bach1 mRNA levels was observed in
9-13 cells (Figure 2B). These results demonstrate that the regulation of miR-196 on Bach1
occurs at a translational level in human hepatoma 9-13 cells.
Bach1 is a well-established transcriptional repressor of the HMOX1 gene (10,11), therefore
we next determined whether down-regulation of Bach1 protein by miR-196 could increase
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HMOX1 gene expression. 9-13 cells were transfected with miR-196 mimic or miRNA
mimic negative control for 48 h, after which the levels of HMOX1 and Cullin 3 (Cul 3, non-
specific gene control) mRNA were quantified by qRT-PCR. As expected, miR-196 mimic
significantly up-regulated HMOX1 mRNA levels by ~2.4 fold (Figure 2C), but not Cul 3
mRNA levels (Figure 2D), compared with the same amount of miRNA mimic negative
control.
miR-196 directly Interacts with the 3′-UTR of Bach1 mRNA in 9-13 cells expressing HCV
non-structural proteins
To further establish that miR-196 targets the 3′-UTR of Bach1 mRNA, which contains two
predicted seed match sites for miR-196 (Figure 3A), [rather than exerting a less direct and
specific regulation], a reporter construct, which we called pGL3-Bach1, with Bach1 3′-UTR
downstream of the firefly luciferase (f-luc) open reading frame (Figure 3B), was used. 9-13
cells were co-transfected with pGL3-Bach1 (f-luc), pRL-TK (renilla, to normalize for
transfection efficiencies), and with miRNA-negative controls, miR-196 mimic or miR-16 (a
“negative” miR with no predicted binding sites in the 3′-UTR of Bach1 mRNA). 48 h after
transfection, the luciferase reporter activity was assayed. miR-196 mimic transfection
significantly decreased reporter activity by ~53%, whereas miRNA mimic negative control
and miR-16 mimic had no effect on reporter luciferase activity (Figure 3C). A similar effect
was observed when we co-transfected 9-13 cells with a reporter construct pLSV40-GL3/
Bach1 containing the full length 3′-UTR of Bach1 mRNA and miR-196 mimic. Specifically,
50 nM of miR-196 mimic decreased the firefly luciferase activity by ~59% (Suppl. Figure
1B), whereas miRNA mimic negative control (MMNC) had no significant effect on reporter
luciferase activity (Suppl. Figure 1C).
Next, we co-transfected 9-13 cells with Luc reporter construct containing a four nucleotide
mutant Bach1 3′-UTR, which we called pGL3-Bach1-Mut (Figure 4A), and with pRL-TK,
and with miR-196 mimic or miR-155 mimic (22) (a “negative” miR, with no changes of
predicted miR-155 binding sites in pGL3-Bach1-WT and pGL3-Bach1-Mut), and assayed
the luciferase reporter activity. miR-196 mimic transfection significantly decreased
luciferase activity in a dose-dependent fashion, whereas miR-196 did not change reporter
activity in cells transfected with the reporter construct containing mutant binding sites for
miR-196 (Figure 4B). miR-155 significantly decreased reporter activity in both pGL3-
Bach1-WT and pGL3-Bach1-Mut (Figure 4C). These results demonstrate that miR-196
directly regulates Bach1 gene expression and miR-196 mediates down-regulation of Bach1
though the 3′-UTR of Bach1 mRNA.
To further establish the direct interaction between miR-196 and Bach1-3′-UTR, we created
mutant miR-196 (Figure 5A) in which seed match sites for the 3′-UTR of Bach1 mRNA
were abolished. Cells were co-transfected with pGL3-Bach1-WT, and with pRL-TK, and
with increasing concentrations of miRNA mimic negative control, miR-196 mimic or
mutant miR-196 mimic, and luciferase reporter activity was assayed. As anticipated,
miR-196 resulted in a significant reduction in luciferase activity in a dose-dependent
fashion, which was consistent with our previous observations, whereas miRNA negative
controls and mutant miR-196 did not affect luciferase activity (Figure 5B), further indicating
the direct interaction between miR-196 and the 3′-UTR of Bach1 mRNA.
We predicted that mutant miR-196 (miR-196-Mut), containing base complementarity with
mutant pGL3-Bach1 (pGL3-Bach1-Mut), should restore its effect on mutant reporter
(Bach1-3′-UTR-Mut) activity, because they again match perfectly in their seed regions
(Figure 5C). As we predicted, mutant miR-196 mimic significantly inhibited luciferase
activity in cells transfected with mutant pGL3-Bach1, which was mutated to “fit” mutant
miR-196, whereas no significant effects of miR-196 wild type on mutant reporter (pGL3-
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Bach1-Mut) luciferase activity were observed, further establishing the direct interaction
between miR-196 and the 3′-UTR of Bach1 mRNA (Figure 5D).
miR-196 represses HCV RNA and protein expression in HCV replicon cells
To determine whether miR-196 represses HCV mRNA and protein expression, HCV
replicon cell lines Con1 and 9-13 cells were transfected with miR-196 mimic or microRNA
mimic negative control. As shown in Figure 6A & B, 50 nM of miR-196 mimic resulted in a
significant reduction of HCV replication by ~50% in Con1 cells and NS5A protein levels by
~52%, compared with the same concentration of miRNA mimic negative control. When
Bach1 gene expression was silenced by Bach1-siRNA (Figure 6C), the levels of HCV
replication were significantly decreased by ~40% (Figure 6D).
Comparative studies of miR-196 on HCV expression in Con1-WT- vs Con1-Mut-transfected
Huh-7.5 cells
Analysis in silico predicts two 6-nt match sites within HCV Con1 genome to a region of
miR-196 (nucleotides 2–7) (Figure 7A), which are not considered as perfect matches of a 7-
nt match to the seed region of the miRNA (nucleotides 2–8), and different from the perfect
seed match between miR-196 and HCV JFH1 genome (18). However there is a possibility
that two 6-nt complementary matches could lead to an effect. Therefore, we investigated
whether the inhibition of HCV expression by miR-196 is the result of an effect through
Bach1 and HMOX1 or by directly targeting the HCV genome, or both. We introduced four
nucleotide mutants to generate mutant pFK-Con1-Mut, in which two match sites for the
HCV Con1 genome were abolished (Figure 7A). 50 nM of miR-196 transfection still
resulted in a significant reduction of HCV core and NS5A expression in Huh-7.5 cells
transfected with Con1-Mut RNA, as observed in Huh-7.5 cells transfected with Con1-WT
RNA (Figure 7B & C), but the effect of miR-196 on HCV core and NS5A in Con1-Mut-
transfected cells was slightly less than that in Con-WT-transfected cell (Figure 7D). These
findings, together with data shown in Figure 6C & D, suggested that the inhibition of HCV
expression by miR-196 is the result of an effect through Bach1 as well as targeting the HCV
Con1 genome, and the indirect effect of miR-196 on HCV expression though Bach1 and
HMOX1 is a major contribution to inhibition of HCV expression.
miR-196 inhibits HCV expression in the HCV JFH1-based cell culture system
As reported recently, a perfect match for miR-196 was found in the coding region of the
HCV NS5A gene in HCV JFH1 genome (18). As expected, we observed a similar down-
regulatory effect of miR-196 on HCV expression in the HCV J6/JFH1 cell culture system.
50 nM of miR-196 led to a significant decrease of HCV J6/JFH1 RNA by nearly 70% in J6/
JFH1 transfected Huh-7.5 cells (Figure 8A), ~50% in J6/JFH1 infected Huh-7.5 cells
(Figure 8B) and ~60% reduction of HCV NS3 protein in J6/JFH1 infected Huh-7.5 cells
(Figure 8C). These results were consistent with previous observations in the JFH1 cell
culture system (18).
DISCUSSION
The major novel findings of this work are that (1) miR-196 has functional binding sites in
the 3′-UTR of Bach1 mRNA and (2) down-regulation of Bach1 by either miR-196 or
Bach1-siRNA represses HCV expression. Functionality of miR-196 in regulation of Bach1
is demonstrated by several lines of evidence, including initial in silico analysis (Figure 1),
by expected effects of miR-196 mimics (Figures 2), and by the expected effects of miR-196
mimics on luciferase reporter constructs containing the wild type and mutant Bach1 3′-UTR
(Figures 3, 4 and 5, and Suppl. Figure 1). In addition, we demonstrate that down-regulation
of Bach1 by either miR-196 or Bach1-siRNA leads to the up-regulation of the HMOX1 gene
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(Figure 2C & D) and to down-regulation of HCV expression in replicon cells (the genotype
1b Con1 strain) (Figure 6) and the HCV J6/JFH1-generated cell culture system (Figure 8).
These results suggest that over-expression or up-regulation of miR-196 represents a
potential new additional therapeutic strategy for chronic HCV infection, as well as other
conditions in which up-regulation of HMOX1 may be desirable.
Based upon a large number of experimental and clinical studies carried out during the past
several years, it is now generally accepted that HCV infection produces an increase in
oxidative stress in infected hepatocytes. One important mediator of such increased oxidative
stress is the HCV core protein (27,28). In parallel with these observations are a series of
observations in numerous systems, including experimental systems with expression of HCV,
showing that HMOX1 helps to protect numerous cells and tissues against the potentially
damaging effects of excess oxidative stress. These actions are based upon the ability of
HMOX1 to decrease “free” or loosely-bound heme, which can act as a potent prooxidant,
and to increase production of carbon monoxide, biliverdin, and bilirubin, which have potent
antioxidant and anti-inflammatory and antifibrogenic effects (6–8,29,30). HMOX1 has also
emerged as an important anti-apoptotic enzyme (31). Over-expression or induction of
HMOX1 suppresses HCV replication and increases resistance of hepatocytes to oxidant
injury (19,20).
Regulation of expression of the HMOX1 gene is complex. However, we and others have
shown that among the important sites for regulation are a series of expanded AP-1 sites, also
called antioxidant responsive elements (31), Maf protein responsive elements [MARE], and
metalloporphyrin-responsive elements [MPRE] in the 5′ untranslated region of HMOX
genes, across many species (32–36). Bach1 plays a key role in tonic repression of expression
of the HMOX1 gene. It does so by forming heterodimers with small Maf proteins and
blocking transcriptional activation of the gene. Bach1 contains several consensus binding
sites (all containing CP motifs), when they bind heme, lead to a change in conformation of
the protein with marked reduction in affinity for Maf proteins and subsequent derepression
and increase in activity of HMOX1 gene expression (9,10,12).
In view of the above, it is not surprising that HMOX1 activity might be increased in HCV
infection, and, indeed, we and others have shown this to be the case (5). Nevertheless, in
some other experimental systems and also in some clinical studies, a decrease in expression
of HMOX1 has been observed in the setting of chronic hepatitis C (37,38). These findings
suggest the possibility that patients with genetic or other factors that lead to lower levels of
HMOX1 gene expression may be at increased risk for development of chronic hepatitis C
infection after acute HCV exposure and/or with greater risks of development of more rapidly
progressive liver disease due to HCV infection. In this regard, there are at least two known
genetic factors that influence levels of expression of HMOX1, namely, the length of GT
repeats in the 5′-untranslated region and the presence of a single nucleotide polymorphism at
position -413 (A/T, rs2071746) in the HMOX1 promoter region (39,40).
The discovery of miRNAs in C. elegans ushered in a new and exciting area of study. The
numbers of miRNAs continues to grow, and additional mRNAs and candidate genes
regulated by them continue to be identified. With respect to the liver, miR-122 was
identified as the most abundant miRNA expressed in hepatocytes (accounting for ~70% of
total miRNA’s) and shown to have major effects on several enzymes of cholesterol
metabolism (41,42). Unexpectedly, miR-122 was also shown to be required for HCV
expression (19,43), at least in cell culture systems. More recent work has shown that the
effects of miR-122 depend upon the context and location of its cognate seed sequence
binding sites. The sites in the 5′ region are mostly associated with up-regulation of
expression, whereas those in the 3′ untranslated region are mostly associated with repression
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of expression (44). Our current work adds miR-196 as a down regulator of HCV expression
(Figure 6 & 8) and an attractive candidate as new therapeutic agents for chronic HCV
infection.
Our study has limitations. Effects of miR-196 on, Bach1, HMOX1, and HCV thus far have
been shown only in cell culture models, and the suppression of HCV expression has been
moderate, not extremely high. The field of HCV research has been stymied by the lack of
simple and robust animal models. Among non-human species, only chimpanzees have thus
far been capable of being infected with HCV, and the disease in them is generally relatively
mild. They are also extraordinarily difficult and expensive to maintain. Recently, murine
models have been developed, based upon immune deficient animals into which human
hepatocytes can be implanted without rejection, and these hepatocytes then infected with the
hepatitis C virus (45,46). Another recent model has been able to establish this in non-
immunodeficient mice in which the host animal hepatocytes undergo necrosis and apoptosis
and can be rescued with human hepatocytes (47). Thus, over-expression of a combination of
miR-196 and other selected miRNAs in order to decrease the viral output further in cell
cultures and murine models are currently under study in our laboratory.
In summary, we demonstrate functional miR-196 binding sites in the 3′-UTR of Bach1,
which lead to down-regulation of Bach1 gene expression, up-regulation of HMOX1 gene
expression, and down-regulation of HCV expression. These findings add to the growing
panoply of miRNAs that influence expression of genes and proteins of the hepatitis C virus
and of HMOX1, a key cytoprotective enzyme. They suggest potential new additional
therapies for chronic HCV infection and, perhaps, for other diseases characterized by
increased oxidative stress.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Abbreviations
BCA Bicinchoninic acid
bZip Basic leucine zipper
CHC chronic hepatitis C
GAPDH Glyceraldehyde-3-phosphate dehydrogenase
HMOX Heme oxygenase
HCV Hepatitis C virus
IFN-α Interferon-alpha
IFN-β Interferon-beta
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MARE Maf recognition element
miRNA microRNA
MMNC miRNA mimic negative control
MINC miRNA inhibitor negative control
Nrf2 Nuclear regulatory factor erythroid 2-related factor 2
NS Nonstructural protein (s) of HCV
NS5A Nonstructural protein 5a of HCV
NQO1, NAD(P)H quinone oxidoreductase
UTR untranslated region
PAGE polyacrylamide gel electrophoresis
PVDF Polyvinylidene fluoride
qRT-PCR Quantitative real time polymerase chain reaction
SDS Sodium dodecyl sulfate
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Figure 1. In silico prediction of putative binding sites for miR-196 in the 3′-UTR of Bach1
(A) Schematic of seed region match between miR-196 and the first putative Bach1 3′-UTR
site targeted. The first site is highly conserved in the human, mouse, rat, dog and pig. (B)
Schematic of second seed region match between miR-196 and the putative Bach1 3′-UTR
site targeted. The second site is poorly conserved in the human, mouse, rat, dog and pig.
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Figure 2. miR-196 mimic down-regulates Bach1 protein levels and up-regulates expression of the
HMOX1 gene in 9-13 cells
9-13 cells were transfected with 50 nM miR-196 mimic or miRNA mimic negative control
(MMNC) by Lipofectamine 2000 as indicated. 24–48 h after transfection, the cells were
harvested. Bach1 protein levels were assessed by Western blots with anti-Bach1 or GAPDH
specific antibodies. The levels of Bach1 mRNA were quantified by qRT-PCR as described
in Materials and Methods. The amounts of Bach1 protein and mRNA were normalized to
GAPDH which did not vary with treatment. Values for cells with a mock transfection were
set equal to 1. The levels of HMOX1 mRNA were quantified by qRT-PCR. The amounts of
HMOX1 mRNA levels were normalized to GAPDH which did not vary with transfection.
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Values for cells with mimic negative control transfection were set equal to 1. Data are
presented as means ± SE, n=3. * differs from negative control only, P<0.05. (A) miR-196
mimic down-regulated Bach1 protein levels. (B) The levels of Bach1 mRNA were not
altered with miR-196 mimic transfection. (C) miR-196 mimic up-regulated HMOX1 mRNA
levels. (D) miR-196 did not alter Cullin 3 mRNA levels.
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Figure 3. miR-196 mimic represses the expression of a luciferase reporter containing Bach1 3′-
UTR
(A) The Bach1 3′-UTR contains two seed match sites (highlighted) for miR-196. (B)
Schematic representation of pGL3-Bach1, the firefly luciferase (f-luc) reporter construct
utilized. (C) Inhibition of the f-luc activities of pGL3-Bach1 3′-UTR reporter by miR-196
mimic. 9-13 cells were co-transfected with 0.4 μg/mL of pGL3-Bach1, 0.4 μg/mL of pRL-
TK (renilla) and with 50 nM miR-196 mimic, miR-16 mimic or miRNA mimic negative
control (MMNC) by Lipofectamine 2000 as indicated. 48 h after transfection, the luciferase
reporter activities were measured using Dual Luciferase Assay System from Promega.
Firefly luciferase activities were normalized to renilla luciferase activities and total protein,
as indicated in Materials and Methods. Values for cells with a mock transfection were set
equal to 1. Data are presented as means ± SE, n=3. * differs from negative control only,
P<0.05.
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Figure 4. miR-196 does not inhibit luciferase activity of reporter with mutant Bach1 3′-UTR
(A) Four nucleotides in two seed match sites of Bach1 3′-UTR were replaced. (B) miR-196
mimic decreased the f-luc activity of pGL3-Bach1-WT but not pGL-Bach1-Mut reporter.
9-13 cells were co-transfected with 0.4 μg/mL of mutant pGL3-Bach1 or 0.4 μg/mL of
pGL3-Bach1 and with 0.4 μg/mL of pRL-TK (renilla), and with miR-196 mimic (10–50
nM) as indicated in Materials and Methods, 48 h after transfection, the luciferase reporter
activities were measured using Dual Luciferase Assay System from Promega, firefly
luciferase activities were normalized to renilla luciferase activities and total protein. (C)
miR-155 mimic decreased the f-luc activities of both pGL3-Bach1-WT and pGL-Bach1-Mut
reporter. 9-13 cells were co-transfected with 0.4 μg/mL of mutant pGL3-Bach1 or 0.4 μg/
mL of pGL3-Bach1 and with 0.4 μg/mL of pRL-TK (renilla), and with miR-155 mimic (10–
50 nM). 48 h after transfection, the luciferase reporter activities were assayed as described in
Materials and Methods. Values for cells with a mock transfection were set equal to 1. Data
are presented as means ± SE, n=3. * differs from negative control only, P<0.05.
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Figure 5. Mutant miR-196 mimic does not alter the luciferase activity of Bach1 3′-UTR reporter
but inhibits the luciferase activity of mutant Bach1 3′-UTR reporter
(A) Four nucleotides mutation were introduced to the seed match sites of miR-196. (B)
Effect of mutant miR-196 on Bach1 3′-UTR reporter activity. 9-13 cells were co-transfected
with 0.4 μg/mL of pGL3-Bach1, 0.4 μg/mL of pRL-TK and with 0, 10, 20 or 50 nM mimic
negative control, miR-196 mimic or mutant miR-196 for 48 h, firefly and renilla luciferase
activities were measured using Dual Luciferase Assay System from Promega. Firefly
luciferase activities were normalized to renilla luciferase activities and total protein, as
indicated in Materials and Methods. Values for cells without microRNA transfection were
set equal to 1. (C) Restoration of seed match between mutant miR-196 and mutant Bach1 3′-
UTR are shown. (D) Inhibition of mutant Bach1 3′-UTR reporter activity by mutant
miR-196 mimic. 9-13 cells were co-transfected with 0.4 μg/mL of mutant reporter (pGL3-
Bach1-Mut), 0.4 μg/mL of pRL-TK, and with 0, 10, 20 or 50 nM mutant miR-196 or wild
type miR-196 mimic for 48 h, firefly and renilla luciferase activities were measured. Firefly
luciferase activities were normalized to renilla luciferase activities and total protein. Values
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for cells without microRNA transfection were set equal to 1. Data are presented as means ±
SE, n=3. * differs from mimic negative control, P<0.05.
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Figure 6. miR-196 mimic represses HCV expression in HCV replicon cells
Cells were transfected for 24-48 h with 10–50 nM miR-196 mimic or Bach1-siRNA by
Lipofectamine 2000, after which cells were harvested and total RNA and protein were
extracted. The levels of HCV core and NS5A and host cell GAPDH mRNA and protein
levels were measured by quantitative RT-PCR and Western blots as described in Materials
and Methods. Data are presented as means ± SE, n=3. * differs from negative control only,
P<0.05. (A) Down-regulation of HCV core and NS5A mRNA expression by miR-196
mimic in Con1 cells. (B) Down-regulation of HCV NS5A protein expression by miR-196
mimic in 9-13 cells. (C) Silencing Bach1 gene expression by Bach1-siRNA in Con1 cells.
(D) Down-regulation of HCV core and NS5A mRNA expression by Bach1-siRNA in Con1
cells.
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Figure 7. Effect of miR-196 on HCV expression in Huh-7.5 cells transfected with Con1-WT or
Con1-Mut RNA
Huh-7.5 cells were transfected with 2 μg/well of HCV Con1-WT or Con-Mut RNA by
Lipofectamine 2000. After 24 h, cells were transfected with 50 nM of miR-196 mimic, or
miRNA mimic negative control (MMNC) as control. After 48 h, cells were harvested and
total proteins were extracted. HCV core, NS5A and GAPDH protein levels were measured
by Western blots. Data are presented as means ± SE, n=3. * differs from control P<0.05. (A)
In silico prediction of putative binding sites for miR-196 in HCV genotype1 Con1 genome
and the four nucleotides mutation introduced to the binding sites of miR-196. (B) Effects of
miR-196 on HCV core and NS5A protein levels in Con1-WT-transfected Huh-7.5 cells. (C)
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Effects of miR-196 on HCV core and NS5A protein levels in Con1-Mut-transfected Huh-7.5
cells. (D) Comparison of the effects in Con1-WT- vs Con1-Mut- transfected Huh-7.5 cells.
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Figure 8. miR-196 mimic inhibits HCV expression in the HCV J6/JFH1-based cell culture system
Huh-7.5 cells were transfected with 2 μg/well of HCV J6/JFH1 RNA by Lipofectamine
2000. After 48 h, cells were transfected with miR-196 mimic, or miRNA mimic negative
control (MMNC). For HCV infection, naïve Huh-7.5 were cultured with 1 mL of cell culture
supernatants harvested from J6/JFH1-transfected cells, as described in Materials and
Methods. After 48 h of exposure to the supernatants, cells were transfected with miR-196
mimic, or miRNA mimic negative control (MMNC) for 48 h. Cells were harvested and total
RNA and proteins were extracted. HCV RNA was quantified by qRT-PCR, and HCV NS3
and GAPDH protein levels were measured by Western blots. Data are presented as means ±
SE, n=3. * differs from control P<0.05. (A) Down-regulation of HCV J6/JFH1 RNA levels
by miR-196 mimic in Huh-7.5 cells transfected with J6/JFH1 RNA. (B) Down-regulation of
HCV J6/JFH1 RNA and (C) protein levels by miR-196 mimic in Huh-7.5 cells infected with
J6/JFH1 hepatitis C virus secreted into the culture supernatant.
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